

2022 China Cancer Immunotherapy Workshop Agenda (draft)

September 2-3 , Beijing, China

Thursday, September 1st (US Eastern Time)		
Time (Eastern)	Topic	Speaker
08:00-8:15 PM	Opening Remarks	Xinyu Weng (CCFDIE) Zihai Li (CAHON)
08:15-10:05 PM	Conference Main Theme Session: The Next Decade in Immuno-Oncology Chairs: Zihai Li (CAHON), Wenru Song (CAHON)	
08:15-08:40 PM	The next chapter in immuno-oncology from the T cell lifestyle perspective	Rafi Ahmed, Emory University
08:40-09:05 PM	Progress with immunotherapy for CAR-T cells	Crystal Mackall, Stanford
09:05-09:30 PM	Roadmap for IO drug approval by European Medicines Agency	Harald Enzmann, Germany
09:30-10:05 PM	Panel discussion	All speakers
10:05-10:15 PM	Break	

10:15-11:55 PM	Session 1: Synthetic Immuno-Oncology Chairs: Delong Liu (CAHON) , Hongtao Liu (CAHON)	
10:15-10:40 PM	Cytokine engineering and therapy	Warren J. Leonard, NIH
10:40-11:05 PM	Advances in CAR-T Therapy Development	Avery Posey, Jr , University of Pennsylvania
11:05-11:30 PM	Bi-specific antibody: targeting tumor cells or immune cells?	Yangxin Fu, School of Medicine, Tsinghua University/CAHON
11:30-11:55 PM	Panel discussion	All speakers
11:55 PM -1:30 AM	lunch	
1:30-3:40 AM	Session 2: Immuno-Oncology Landscape in China Chairs: CCFDIE	
1:30-1:55 AM	Landscape and consecutive perspectives in immunotherapy for hepatobiliary cancer in China	Haitao Zhao, Peking Union Medical College Hospital
1:55-2:20 AM	Advances in CAR-T research for gastrointestinal tumors	Lin Shen, Peking University Cancer Hospital
2:20-2:45 AM	How to further improve the efficacy of immunotherapy for gastrointestinal cancer	Ruihua Xu, Sun Yat-sen University Cancer Center
2:45-3:10 AM	Clinical research progress of Car-T for multiple myeloma	Chunrui Li, Tongji Hospital
3:10-3:30 AM	Panel discussion	All speakers
3:30-3:40 AM	Break	

3:40-4:30 AM	Session 3: Perspective from Biopharma Industry Chairs: Steve Chin (CAHON), Michael Liao (CAHON)	
3:40-3:50 AM	Roche/Genentech Oncology -Circulating tumor DNA in Drug Development	David Shames, Roche/Genentech
3:50-4:00 AM	Perspective from Junshi Biosciences and TopAlliance Biosciences	Patricia Keegan, TopAlliance Biosciences, Inc.
4:00-4:10 AM	Making Neoadjuvant Immunotherapy a Reality	Junliang Cai, BMS
4:10-4:20 AM	Early Development Compounds in BI Therapeutic Area Oncology (Selection)	Michael Merger, BI
4:20-4:30 AM	Innovative immune cell therapy drug development and practice guided by clinical value	Lulu Lyu, Juventas

Friday, September 2nd (US Eastern Time)		
Time (Eastern)	Topic	Speaker
8:00-09:45 PM	Session 4: Metabolism and Therapeutic Opportunities in Immuno-Oncology Chairs: Lei Zheng (CAHON), Liang Deng (CAHON)	
8:00-8:25 PM	Mitochondrial Shape-Shifting in the T cell Response	Erika L. Pearce, Johns Hopkins
8:25-8:50 PM	Targeting metabolic checkpoint in macrophage for cancer immunotherapy	Ping-Chih Ho, Ludwig Institute for Cancer Research, Lausanne
8:50-9:15 PM	Systems immuno-oncology for discovering key metabolic checkpoint for cancer immuno-therapy	Hongbo Chi, St. Jude Children's Research Hospital
9:15-9:35 PM	Panel discussion	All speakers
9:35-9:45 PM	Break	
9:45 -11:45 PM	Session 5: What Is the Next anti-PD-1 in IO? Chairs: Siwen Hu-Lieskovan (CAHON), Christine Ye (CAHON)	
09:45-10:10 PM	LAG3: the third checkpoint inhibitor	Dario Vignali, Univ of Pitts
10:10-10:35 PM	Considerations for SCLC immunotherapy: where do we go after anti-TIGIT?	Charles M. Rudin, Memorial Sloan Kettering Cancer Center
10:35-11:00 PM	Is there a future for TGFbeta-targeting in IO?	Zihai Li, OSU/CAHON
11:00-11:25 PM	IDO pathway inhibition: epic fail or novel therapeutic opportunity?	Jason Luke, MD, University of Pittsburg
11:25-11:45 PM	Panel discussion	All speakers

11:45 PM -1:30 AM	Lunch				
1:30 -3:30 AM	Session 6: Regulatory consideration				
Parallel Sub-session 1:Cell Therapy Regulation			Parallel Sub-session 2:IO Drug Regulation		
Time	Topic	Speaker	Time	Topic	Speaker
1:30 -2:00 AM	Clinical consideration for cancer cell therapy - US FDA Perspective	Yuxia Jia, FDA/CAHON	1:30 -1:55 AM	Focus Points of Pharmaceutical Research and Evaluation of Antibody Drugs	Suyuan Cheng, CDE
2:00 -2:30 AM	Progress of Pharmaceutical Evaluation of Cell and Gene Therapy Products	Longchang Xu, CDE	1:55 -2:20 AM	Non-clinical Research of Tumor Immunotherapy Drugs	Bing Yu, CDE
2:30 -3:00 AM	Progress of Pharmacological and Toxicological Evaluation of Cell and Gene Therapy	Xuan Ye,CDE	2:20 -2:45 AM	Statistical Considerations in Therapeutic Efficacy Evaluation of Immunotherapy	Ruobing Li, CDE
3:00 -3:30 AM	Technical Requirements on Post-marketing Research of CAR-T Cell Products car-t cell products	Yunhong Huang, CDE	2:45 -3:05 AM	Considerations for Evaluation of Clinical Development of Gynecological Oncology	Hong Zhang, CDE

3:30 -4:00 AM	Considerations for Evaluation of Clinical Research of Oncotherapy Vaccine	Jianchao Gao,CDE	3:05 -3:10AM	Remarks	Zhimin Yang, CDE
4:00 -4:30 AM	Considerations for Clinical Test Statistics of Cell and Gene Therapy Products	Jianhong Pan, CDE	3:10 -3:35 AM	Considerations for Evaluation of Clinical Development of Gastrointestinal Tumor Immunotherapy	Ruimin Hao, CDE
				Remarks	Xia Lin, CDE
4:30 -3:00 AM	Discussion	All speakers	3:35 -4:00 AM	Considerations for Evaluation of Clinical Development of Anti-tumor Double-antibody Drugs	Yuanyuan Song,CDE
				Remarks	Ling Tang, CDE
			4:00 -4:25 AM	Considerations for Evaluation of Immunotherapy Risk Control	Wenjuan Hu, CDE
				Remarks	Xin Tong, CDE
4:25-4:45 AM	Conclusion and Discussion	All speakers			